Publications

Found 154 results
Type [ Year(Desc)]
2012
LR Polstein, and CA Gersbach. "Photoregulated gene expression in human cells with light-inducible engineered transcription factors." ASME 2012 Summer Bioengineering Conference, SBC 2012 (2012): 351-352.
2013
DG Ousterout, P Perez-Pinera, PI Thakore, AM Kabadi, MT Brown, X Qin, O Fédrigo, V Mouly, JP Tremblay, and CA Gersbach. "Erratum: Reading Frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients (Molecular Therapy (2013) 21 (1718-1726) DOI: 10.1038/mt.2013.111)." Molecular Therapy 21, no. 11 (2013): 2130.
CL Duvall, A Prokop, CA Gersbach, and JM Davidson. "Gene Delivery into Cells and Tissues." (2013): 687-723.
MS Bhakta, IM Henry, DG Ousterout, KT Das, SH Lockwood, JF Meckler, MC Wallen, A Zykovich, Y Yu, H Leo et al. "Highly active zinc-finger nucleases by extended modular assembly." Genome research 23, no. 3 (2013): 530-538.
DW Dumbauld, TT Lee, A Singh, J Scrimgeour, CA Gersbach, EA Zamir, J Fu, CS Chen, JE Curtis, SW Craig et al. "How vinculin regulates force transmission." Proceedings of the National Academy of Sciences of the United States of America 110, no. 24 (2013): 9788-9793.
DG Ousterout, P Perez-Pinera, PI Thakore, AM Kabadi, MT Brown, X Qin, O Fédrigo, V Mouly, JP Tremblay, and CA Gersbach. "Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients." Molecular Therapy 21, no. 9 (2013): 1718-1726.
P Perez-Pinera, DD Kocak, CM Vockley, AF Adler, AM Kabadi, LR Polstein, PI Thakore, KA Glass, DG Ousterout, KW Leong et al. "RNA-guided gene activation by CRISPR-Cas9-based transcription factors." Nature Methods 10, no. 10 (2013): 973-976.
TM Gibson, and CA Gersbach. "The role of single-cell analyses in understanding cell lineage commitment." Biotechnology journal 8, no. 4 (2013): 397-407.
P Perez-Pinera, DG Ousterout, JM Brunger, AM Farin, KA Glass, F Guilak, GE Crawford, AJ Hartemink, and CA Gersbach. "Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." In MOLECULAR THERAPY, S93. Vol. 21. 2013.
P Perez-Pinera, DG Ousterout, JM Brunger, AM Farin, KA Glass, F Guilak, GE Crawford, AJ Hartemink, and CA Gersbach. "Synergistic and tunable human gene activation by combinations of synthetic transcription factors." Nat Methods 10, no. 3 (2013): 239-242.
CA Gersbach, and CF Barbas. "Targeted plasmid integration into the Human Genome by engineered recombinases." Topics in Current Genetics 23 (2013): 267-284.
JP Tremblay, X Xiao, A Aartsma-Rus, C Barbas, HM Blau, AJ Bogdanove, K Boycott, S Braun, XO Breakefield, JA Bueren et al. "Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases." Molecular therapy : the journal of the American Society of Gene Therapy 21, no. 2 (2013): 266-268.
KA Glass, JM Brunger, CA Gersbach, and F Guilak. "Tunable expression of IL-1Ra in genetically modified mesenchymal stem cells for cartilage tissue engineering." In Osteoarthritis and Cartilage, S282-S283. Vol. 21. 2013.
T Gaj, CA Gersbach, and CF Barbas. "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering." Trends in biotechnology 31, no. 7 (2013): 397-405.
2014
CA Gersbach, and P Perez-Pinera. "Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert opinion on therapeutic targets 18, no. 8 (2014): 835-839.
CA Gersbach, T Gaj, and CF Barbas. "Comparing genome editing technologies." Genetic Engineering and Biotechnology News 34, no. 5 (2014): 1, 32-34.
K High, PD Gregory, and C Gersbach. "CRISPR technology for gene therapy." Nature medicine 20, no. 5 (2014): 476-477.
S Chakraborty, H Ji, AM Kabadi, CA Gersbach, N Christoforou, and KW Leong. "A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem cell reports 3, no. 6 (2014): 940-947.
AM Kabadi, and CA Gersbach. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods 69, no. 2 (2014): 188-197.
AM Kabadi, and CA Gersbach. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods (San Diego, Calif.) 69, no. 2 (2014): 188-197.
CA Gersbach. "Genome engineering: the next genomic revolution." Nature methods 11, no. 10 (2014): 1009-1011.
LR Polstein, and CA Gersbach. "Light-inducible gene regulation with engineered zinc finger proteins." Methods in molecular biology (Clifton, N.J.) 1148 (2014): 89-107.
AM Kabadi, DG Ousterout, IB Hilton, and CA Gersbach. "Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector." Nucleic acids research 42, no. 19 (2014).
E Schulz, T Bergmann, M Gebbing, V Schildgen, O Schildgen, C Gersbach, and A Ehrhardt. "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In MOLECULAR THERAPY, S126-S127. Vol. 22. 2014.
JM Brunger, NPT Huynh, CM Guenther, P Perez-Pinera, FT Moutos, J Sanchez-Adams, CA Gersbach, and F Guilak. "Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage." Proceedings of the National Academy of Sciences of the United States of America 111, no. 9 (2014): E798-E806.

Pages